IGF2 and cancer: Despite the fact that, to date, no large-scale studies have yet been produced to determine the rate of solid cancers expressing/secreting IGF-II, the DepMap analysis from patient-derived cancer cells conveyed in Figure 3B suggests that such a number may exceed 65% percent.